FENNEC PHARMACEUTICALS INC. Quarterly Entity Common Stock, Shares Outstanding from Q2 2011 to Q2 2024

Taxonomy & unit
dei: shares
Description
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
Summary
Fennec Pharmaceuticals Inc. quarterly Entity Common Stock, Shares Outstanding history and growth rate from Q2 2011 to Q2 2024.
  • Fennec Pharmaceuticals Inc. Entity Common Stock, Shares Outstanding for the quarter ending August 8, 2024 was 27.4M shares, a 3% increase year-over-year.
Entity Common Stock, Shares Outstanding, Quarterly (shares)
Entity Common Stock, Shares Outstanding, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q2 2024 27.4M +798K +3% Aug 8, 2024 10-Q 2024-08-13
Q1 2024 27.1M +688K +2.61% Mar 25, 2024 10-K 2024-03-29
Q3 2023 26.6M +397K +1.51% Nov 3, 2023 10-Q 2023-11-09
Q2 2023 26.6M +499K +1.92% Aug 2, 2023 10-Q 2023-08-07
Q1 2023 26.4M +398K +1.53% Mar 27, 2023 10-K 2023-03-29
Q3 2022 26.2M +231K +0.89% Nov 11, 2022 10-Q 2022-11-14
Q2 2022 26.1M +60.4K +0.23% Aug 11, 2022 10-Q 2022-08-12
Q1 2022 26M +10.7K +0.04% Feb 25, 2022 10-K 2022-02-28
Q3 2021 26M +197K +0.76% Nov 9, 2021 10-Q 2021-11-10
Q2 2021 26M +651K +2.57% Aug 9, 2021 10-Q 2021-08-10
Q1 2021 26M +647K +2.55% Mar 29, 2021 10-K 2021-03-30
Q3 2020 25.8M +5.91M +29.7% Nov 11, 2020 10-Q 2020-11-16
Q2 2020 25.4M +5.46M +27.4% Aug 4, 2020 10-Q 2020-08-05
Q1 2020 25.4M +5.46M +27.4% May 13, 2020 10-Q 2020-05-14
Q4 2019 19.9M Feb 11, 2020 10-K 2020-02-14
Q3 2019 19.9M +167K +0.85% Nov 12, 2019 10-Q 2019-11-12
Q2 2019 19.9M +963K +5.08% Aug 9, 2019 10-Q 2019-08-09
Q1 2019 19.9M +1.43M +7.75% Mar 11, 2019 10-K 2019-03-15
Q3 2018 19.7M +3.86M +24.3% Nov 13, 2018 10-Q 2018-11-13
Q2 2018 18.9M -15.6B Aug 13, 2018 10-Q 2018-08-13
Q1 2018 18.5M +4.82M +35.3% Mar 16, 2018 10-K 2018-03-28
Q3 2017 15.9M +2.23M +16.3% Nov 13, 2017 10-Q 2017-11-13
Q2 2017 15.6B* +15.6B Aug 14, 2017 10-Q 2017-08-14
Q1 2017 13.6M +2.7M +24.7% Mar 17, 2017 10-K 2017-03-29
Q3 2016 13.6M +2.7M +24.7% Nov 11, 2016 10-Q 2016-11-14
Q2 2016 13.6M +2.72M +24.9% Aug 12, 2016 10-Q 2016-08-12
Q1 2016 10.9M +320K +3.01% Mar 18, 2016 10-K 2016-03-28
Q3 2015 10.9M +1.08M +10.9% Nov 12, 2015 10-Q 2015-11-12
Q2 2015 10.9M -18.7M -63.1% Aug 11, 2015 10-Q 2015-08-11
Q1 2015 10.6M -18.7M -63.8% Mar 16, 2015 10-K 2015-03-31
Q3 2014 9.86M -15.3M -60.8% Nov 13, 2014 10-Q 2014-11-13
Q2 2014 29.6M +4.42M +17.6% Aug 8, 2014 10-Q 2014-08-11
Q1 2014 29.3M +4.15M +16.5% Mar 14, 2014 10-K 2014-03-31
Q3 2013 25.2M 0 0% Nov 10, 2013 10-Q 2013-11-18
Q2 2013 25.2M +243 +0% Aug 10, 2013 10-Q 2013-08-09
Q1 2013 25.2M 0 0% Mar 16, 2013 10-K 2013-04-01
Q3 2012 25.2M 0 0% Nov 10, 2012 10-Q 2012-11-14
Q2 2012 25.2M -428M -94.4% Aug 10, 2012 10-Q 2012-08-13
Q1 2012 25.2M Mar 16, 2012 10-K 2012-03-27
Q3 2011 25.2M Nov 12, 2011 10-Q 2011-11-14
Q2 2011 453M Aug 12, 2011 10-Q 2011-08-15
* An asterisk sign (*) next to the value indicates that the value is likely invalid.